BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation

Reuters

07/28

<a href="https://laohu8.com/S/BLFS">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation

BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554779426"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554779426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554779426?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554779426","market":"us","top_or_hot":-1,"title":"BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BLFS\">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BLFS\">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL3NN6Bj:1","article_id":"2554779426","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554779426","pubTimestamp":1753704323,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BLFS":"BioLife Solutions Inc.","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4198":"医疗保健用品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"BioLife Solutions Inc.向Pluristyx投资200万美元，扩大细胞治疗创新战略合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":0.9},"content_text":"BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n    \n\n        BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}